Windlas Biotech growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+19.0%	+20.8%
EBITDA	+11.2%	+20.2%
Net Income	+9.5%	+15.9%
EPS (adj.)	+9.5%	+15.9%
Total Assets	+19.3%	+19.7%
Total Equity	+14.8%	+13.0%
Free Cash Flow	+132.5%	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

WINDLAS₹888.70

Windlas Biotech Limited

· Pharma & Health

₹ CrorePeersHESTERBIO INDOCO SAIPARENT SYNCOMF PANACEABIO NGLFINE HIKAL JAGSNPHARMMcap ₹1,876 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+19.0	+20.8
EBITDA	+11.2	+20.2
Net Income	+9.5	+15.9
EPS (adj.)	+9.5	+15.9
Total Assets	+19.3	+19.7
Total Equity	+14.8	+13.0
Free Cash Flow	+132.5	—

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.